Zepbound (Tirzepatide) for Prader-Willi Syndrome in a 28-Year-Old
There is insufficient evidence to recommend tirzepatide (Zepbound) for Prader-Willi syndrome, and it should not be used outside of carefully monitored research settings for this specific condition.
Critical Context: Prader-Willi Syndrome is Not Standard Obesity
Prader-Willi syndrome (PWS) represents a fundamentally different pathophysiology than typical obesity. The hyperphagia in PWS stems from hypothalamic dysfunction causing insatiable appetite and lack of satiety signaling—not the metabolic dysregulation that tirzepatide targets in standard obesity 1.
Evidence Landscape
What We Know About Tirzepatide in General Obesity
For adults with standard obesity, tirzepatide demonstrates robust efficacy with mean weight loss of 15-21% depending on dose (5-15 mg weekly) over 72 weeks 2, 3. The 2025 BMJ guidelines provide a weak recommendation in favor of tirzepatide for adults with obesity, acknowledging moderate certainty evidence for weight loss but low to very low certainty for cardiovascular and kidney outcomes 1.
The Critical Gap: Prader-Willi Syndrome
No published studies exist examining tirzepatide specifically in PWS patients. The only relevant evidence comes from older GLP-1 receptor agonists (exenatide and liraglutide—not tirzepatide) in a systematic review of just 23 PWS patients 4. That review showed:
- Mixed results with weight loss (some patients improved, others did not)
- Potential appetite improvement in 5 patients who had this measured
- No serious adverse events reported
- Critical limitation: The authors explicitly concluded there is insufficient evidence to recommend GLP-1 receptor agonists for PWS at present 4
Why This Matters
Tirzepatide is a dual GIP/GLP-1 agonist—mechanistically different from the single GLP-1 agonists studied in PWS 2. While one case series showed tirzepatide effectiveness in Alström syndrome (another rare obesity syndrome) 5, Alström syndrome has different pathophysiology than PWS. Extrapolating these results to PWS would be inappropriate.
Clinical Reasoning Against Use
The hypothalamic dysfunction in PWS may not respond to incretin-based therapies the same way metabolic obesity does. PWS patients have:
- Profound hyperphagia from central nervous system dysfunction
- Abnormal satiety signaling that may not be correctable with GLP-1/GIP agonism
- Complex behavioral and developmental issues requiring specialized management 6
Safety concerns are amplified in PWS:
- Gastrointestinal adverse events (nausea, vomiting, diarrhea) occur in the majority of tirzepatide users 7, 3
- PWS patients already have complex gastrointestinal issues and behavioral challenges
- The risk-benefit calculation differs substantially from standard obesity
What Should Be Done Instead
For this 28-year-old with PWS:
Maintain current evidence-based PWS management: Dietary supervision, behavioral modifications, and growth hormone therapy (the only FDA-approved medication for PWS) 6
Consider research participation: If tirzepatide is to be tried, it should only occur within a formal clinical trial with appropriate monitoring and PWS-specific outcome measures
If metabolic complications exist (type 2 diabetes, cardiovascular disease): Standard therapies for these conditions should be used based on their specific indications, not for PWS-related hyperphagia
The Bottom Line
The absence of PWS-specific data, combined with the mechanistic uncertainty of whether tirzepatide addresses the central pathology of PWS hyperphagia, makes off-label use inappropriate. The 2025 review of PWS pharmacological management confirms that hyperphagia treatments remain an unmet need with no FDA-approved options beyond growth hormone 6. Until PWS-specific trials demonstrate safety and efficacy, tirzepatide should not be used for this indication.